Cargando…

Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study

INTRODUCTION: Epicardial fat (EF) was reported to be independently associated with cardiovascular disease regardless of obesity. We have previously reported that a sodium-glucose co-transporter-2 (SGLT2) inhibitor, luseogliflozin, reduces the EF volume (EFV) in parallel with the reduction of body we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukuda, Tatsuya, Bouchi, Ryotaro, Terashima, Masahiro, Sasahara, Yuriko, Asakawa, Masahiro, Takeuchi, Takato, Nakano, Yujiro, Murakami, Masanori, Minami, Isao, Izumiyama, Hajime, Hashimoto, Koshi, Yoshimoto, Takanobu, Ogawa, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544615/ https://www.ncbi.nlm.nih.gov/pubmed/28616806 http://dx.doi.org/10.1007/s13300-017-0279-y

Ejemplares similares

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
por: Bouchi, Ryotaro, et al.
Publicado: (2017)

Is visceral adiposity a modifier for the impact of blood pressure on arterial stiffness and albuminuria in patients with type 2 diabetes?
por: Bouchi, Ryotaro, et al.
Publicado: (2016)

Indirect measure of visceral adiposity ‘A Body Shape Index’ (ABSI) is associated with arterial stiffness in patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2016)

Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2016)

Ratio of visceral‐to‐subcutaneous fat area predicts cardiovascular events in patients with type 2 diabetes
por: Fukuda, Tatsuya, et al.
Publicado: (2017)

Gender difference in the impact of gynoid and android fat masses on the progression of hepatic steatosis in Japanese patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2017)

Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2017)

Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: a cross-sectional study
por: Fukuda, Tatsuya, et al.
Publicado: (2017)

High visceral fat with low subcutaneous fat accumulation as a determinant of atherosclerosis in patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2015)

Suppression of Extrapancreatic Glucagon by Octreotide May Reduce the Fasting and Postprandial Glucose Levels in a Diabetic Patient after Total Pancreatectomy
por: Okuma, Hideyuki, et al.
Publicado: (2017)

Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: a retrospective observational study
por: Fukuda, Tatsuya, et al.
Publicado: (2018)

Retrograde pyelonephritis and lumbar spondylitis as a result of Salmonella typhi in a type 2 diabetes patient with neurogenic bladder
por: Fukuda, Tatsuya, et al.
Publicado: (2015)

Impact of increased visceral adiposity with normal weight on the progression of arterial stiffness in Japanese patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2015)

Sarcopenia is associated with incident albuminuria in patients with type 2 diabetes: A retrospective observational study
por: Bouchi, Ryotaro, et al.
Publicado: (2017)

Increased visceral adiposity with normal weight is associated with the prevalence of non‐alcoholic fatty liver disease in Japanese patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2015)

Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy
por: Nakano, Yujiro, et al.
Publicado: (2018)

Repeated Hypoglycemic Episodes with Postprandial Hyperinsulinemia after the Recovery from Acute Weight Loss Revealed by Continuous Glucose Monitoring and the Oral Glucose Tolerance Test
por: Masuda, Seizaburo, et al.
Publicado: (2017)

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
por: Kamezaki, Michitsugu, et al.
Publicado: (2018)

Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes
por: González, N., et al.
Publicado: (2017)

COVID-19 and Obesity: Role of Ectopic Visceral and Epicardial Adipose Tissues in Myocardial Injury
por: Lasbleiz, Adèle, et al.
Publicado: (2021)

Stereological Estimation of Myocardial Fat and Its Associations with Obesity, Epicardial, and Visceral Adipose Tissue
por: Holm, Pernille Heimdal, et al.
Publicado: (2022)

A Case of Refractory Hypothyroidism due to Poor Compliance Treated with the Weekly Intravenous and Oral Levothyroxine Administration
por: Nakano, Yujiro, et al.
Publicado: (2019)

Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling
por: Suga, Takayoshi, et al.
Publicado: (2020)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Is the Measurement of Epicardial Fat in Obese Adolescents Valuable?
por: Shin, Joon-Han
Publicado: (2012)

Epicardial Adiposity in Children with Obesity and Metabolic Syndrome
por: Eren, Erdal, et al.
Publicado: (2014)

Bitemporal Obesity: An Overlooked Sign of Visceral Obesity?
por: Abrahim, Mohammed
Publicado: (2022)

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
por: Komiya, Chikara, et al.
Publicado: (2016)

Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules
por: Hosokawa, Kohshiro, et al.
Publicado: (2019)

A Comparative Study of Epicardial Fat Thickness and its Association with Abdominal Visceral Fat Thickness in Obese and Nonobese Type 2 Diabetes Subjects
por: Jain, Siddharth, et al.
Publicado: (2015)

Analysis of probable lipotoxic damage and myocardial fibrosis in epicardial obesity
por: Chumakova, Galina, et al.
Publicado: (2021)

Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study
por: Koshizaka, Masaya, et al.
Publicado: (2020)

Visceral Obesity If Associated with Gallbladder Polyps
por: Lee, Jun Kyu, et al.
Publicado: (2016)

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus
por: Kawata, Takehiro, et al.
Publicado: (2017)

The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial
por: Christensen, Regitse Højgaard, et al.
Publicado: (2018)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Epicardial Adipose Tissue Thickness in Young Indian Overweight and Obese Individuals
por: Shah, AA, et al.
Publicado: (2014)

Epicardial Adipose Tissue Accumulation and Essential Hypertension in Non-Obese Adults
por: Austys, Donatas, et al.
Publicado: (2019)

Obesity and diabetes are major risk factors for epicardial adipose tissue inflammation
por: Vyas, Vishal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4rf4hjt9jutr26q01bea7phjei